(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 16-cent second-quarter 2009 dividend on the company’s common stock, payable June 2, 2009, to shareholders of record at the close of business on May 8, 2009.
The second-quarter 2009 cash dividend will be the 282nd consecutive quarterly dividend paid by Pfizer.
At the company’s Annual Meeting of Shareholders, Chairman and Chief Executive Officer Jeffrey B. Kindler said Pfizer has streamlined operations, reduced bureaucracy, set clear expectations and increased accountability, which has better positioned the company to combine with Wyeth.
“The combination of Pfizer and Wyeth will allow us to advance each and every one of the key growth strategies that will drive our success in the years ahead,” Mr. Kindler said. “Pfizer plus Wyeth will help us extend our leadership in global healthcare in both developed and developing markets. This includes leadership in primary and specialty care; in vaccines, biologics and small molecules; and in animal health, consumer health and nutritionals.”
At the meeting, the company’s 14 directors were re-elected to one-year terms. In addition, shareholders ratified the selection of KPMG LLP as Pfizer’s independent registered public accounting firm for the 2009 fiscal year and voted in support of a revised company stock plan.
In other voting, preliminary results indicate that shareholders approved non-binding proposals requesting that they be provided the opportunity at each annual shareholder meeting to vote on an advisory resolution about executive compensation and that holders of 10% of common stock be provided the ability to call a special shareholder meeting. In 2008, Pfizer amended its bylaws to give holders of 25% or more of common stock the right to call a special meeting.
Two other shareholder resolutions did not receive majority approval.
The final results are subject to verification by the independent election inspectors, which should not significantly change the preliminary results. The final results will appear in Pfizer’s next 10-Q report.
Pfizer Inc: Working together for a healthier world™
Founded in 1849, Pfizer is the world's premier biopharmaceutical company taking new approaches to better health. We discover, develop, manufacture and deliver quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. We also partner with healthcare providers, governments and local communities around the world to expand access to our medicines and to provide better quality health care and health system support. At Pfizer, more than 80,000 colleagues in more than 90 countries work every day to help people stay happier and healthier longer and to reduce the human and economic burden of disease worldwide.
DISCLOSURE NOTICE: The information contained in this release is as of April 23, 2009. The Company assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events or developments.
This release contains forward-looking information about the Company’s business plans, prospects and expectations, including the projected benefits of the proposed acquisition of Wyeth,that involves substantial risks and uncertainties. A description of these risks and uncertainties can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and in its reports on Forms 10-Q and 8-K.
Joan Campion, 212-733-2798
Suzanne Harnett, 212-733-8009